Serotonin in human eating disorders.
The onset and progression of symptomatology in patients with anorexia nervosa and bulimia nervosa is complex. It is unlikely that dysregulation of a single neurotransmitter system would be sufficient to explain the pathophysiology of these disorders. The studies reviewed above provide preliminary evidence that decreased central serotonin function may contribute to the onset or persistence of binge eating episodes in patients with bulimia nervosa, including low weight anorexic patients with bulimic symptoms. Future clinical studies will benefit from the availability of selective serotonin receptor agonists and antagonists. Longitudinal studies through progressive phases of treatment and clinical remission will be important to clarify the contribution of dietary and body weight changes to results of neurotransmitter studies with eating disorder patients.
Jimerson
D C
DC
Department of Psychiatry, Beth Israel Hospital, Boston, Massachusetts 02215.
Lesem
M D
MD
Hegg
A P
AP
Brewerton
T D
TD
D000856:Anorexia Nervosa / Q000503:physiopathology; D002032:Bulimia / Q000188:drug therapy / Q000503:physiopathology; D005247:Feeding Behavior; D001068:Feeding and Eating Disorders / Q000503:physiopathology*; D005277:Fenfluramine / Q000627:therapeutic use; D006801:Humans; D012701:Serotonin / Q000502:physiology*
D005277:Fenfluramine; D012701:Serotonin